Respiratory Transformation Partnership

Asthma and chronic obstructive pulmonary disease (COPD) together affect millions of people across England and are responsible for a high burden of avoidable hospital admissions, significant health inequalities, and substantial costs to the NHS. Despite advances in medicines, inhaler technologies, diagnostics, and digital tools, uptake and equitable access to innovation and outcomes in respiratory care remains inconsistent. This engagement represents an opportunity for industry partners to come together with the NHS to explore how innovative medicines, devices, diagnostics and digital solutions can be safely and effectively introduced into asthma and COPD pathways. The aim is to accelerate access to innovation, improve respiratory outcomes, and support the delivery of more sustainable models of care. The objectives of this engagement are to: - Identify and engage potential industry partners with innovative asthma and COPD medicines (including biologics and inhaled therapies) that could support the Respiratory Transformation Partnership. - Recognise innovations in diagnostics, devices and digital tools where these directly enable or enhance the uptake, safe use, and equitable access to respiratory medicines. - Understand potential forms of contribution from industry partners on anon-exclusive basis, - Take stock of the medicine innovation landscape and pipeline to inform Health Innovation Network support for innovators and to shape future partnership models. This is not a call for competition and there is no planned procurement activity or funding available for potential partners at this stage. Insights gathered will be used to shape future policy, strategy and potential partnership models. HIOTV are making use of the Atamis/FTS channel as the existing infrastructure to maximise potential engagement, and have chosen to issue this as a Prior Information Notice as it is the most appropriate notice type to ensure maximum reach. To reiterate, no public contracts will be awarded as a direct result of this engagement. Participation HIOTV is inviting organisations who meet the following Eligibility Criteria: - organisations that are currently marketing asthma or COPD medicines in the UK, or that have such medicines in development with a marketing authorisation for UK use likely to besought within the next three years. - organisations innovations likely to improve access to innovative medicines or improve care pathways for asthma and COPD patients are also welcome to contribute. HIOTV is offering the opportunity for Respondents to: - Complete an online Questionnaire("Questionnaire"); and - If deemed appropriate attend a one-to-one Engagement Meeting to assesspotential areas of partnership Engagement meetings are expected to be held between 1st October and 10thOctober 2025. HIOTV will use reasonable endeavours to accommodate all interested respondents within this window. Additional information: All Respondents will be asked to complete a Questionnaire, accessible on request from hin-rtp@healthinnovationoxford.org Respondents may also submit additional documents as part of their Response. Individual survey responses will be only made available to teams developing the Respiratory Transformation Partnership within HIOTV and the Office for LifeScience. A summary of insights (non-attributable and anonymised) will be published on the Atamis portal. Further phases of consultation may be planned during 2025 in respect of enabling access to innovative medicines and technologies for asthma and COPD. You can opt-in to be notified of these opportunities via the Questionnaire and/or by contacting HIOTV at: hin-rtp@healthinnovationoxford.org Responses to the Questionnaire should be submitted by 29th Sept 2025.